NO328762B1 - Anvendelse av klostridiumtoksin eller kompleks derav for fremstilling av et terapeutisk middel - Google Patents
Anvendelse av klostridiumtoksin eller kompleks derav for fremstilling av et terapeutisk middel Download PDFInfo
- Publication number
- NO328762B1 NO328762B1 NO20012716A NO20012716A NO328762B1 NO 328762 B1 NO328762 B1 NO 328762B1 NO 20012716 A NO20012716 A NO 20012716A NO 20012716 A NO20012716 A NO 20012716A NO 328762 B1 NO328762 B1 NO 328762B1
- Authority
- NO
- Norway
- Prior art keywords
- bont
- toxin
- complex
- clostridial toxin
- clostridium toxin
- Prior art date
Links
- 239000003053 toxin Substances 0.000 title claims abstract description 33
- 231100000765 toxin Toxicity 0.000 title claims abstract description 33
- 241000193403 Clostridium Species 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 206010041235 Snoring Diseases 0.000 claims abstract description 19
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 claims abstract description 10
- 101710117524 Botulinum neurotoxin type B Proteins 0.000 claims abstract description 8
- 101710117520 Botulinum neurotoxin type F Proteins 0.000 claims abstract description 6
- 101000933563 Clostridium botulinum Botulinum neurotoxin type G Proteins 0.000 claims abstract description 6
- 101000985020 Clostridium botulinum D phage Botulinum neurotoxin type D Proteins 0.000 claims abstract description 6
- 101710117515 Botulinum neurotoxin type E Proteins 0.000 claims abstract description 5
- 239000000185 hemagglutinin Substances 0.000 claims abstract description 5
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 4
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 239000002502 liposome Substances 0.000 claims abstract description 3
- 231100001102 clostridial toxin Toxicity 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 15
- 108030001720 Bontoxilysin Proteins 0.000 claims description 11
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 101000985023 Clostridium botulinum C phage Botulinum neurotoxin type C Proteins 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 description 21
- 210000003205 muscle Anatomy 0.000 description 20
- 239000002581 neurotoxin Substances 0.000 description 11
- 231100000618 neurotoxin Toxicity 0.000 description 11
- 206010033799 Paralysis Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 101710138657 Neurotoxin Proteins 0.000 description 6
- 210000003254 palate Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000004927 fusion Effects 0.000 description 4
- 230000010355 oscillation Effects 0.000 description 4
- 210000001584 soft palate Anatomy 0.000 description 4
- 108010055044 Tetanus Toxin Proteins 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000003699 striated muscle Anatomy 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 229940118376 tetanus toxin Drugs 0.000 description 3
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 3
- 206010049816 Muscle tightness Diseases 0.000 description 2
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 2
- 206010067672 Spasmodic dysphonia Diseases 0.000 description 2
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 2
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 2
- 102000050389 Syntaxin Human genes 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 208000018197 inherited torticollis Diseases 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000003320 palatal muscle Anatomy 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- 201000002849 spasmodic dystonia Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 1
- 101000761935 Clostridium botulinum Botulinum neurotoxin type X Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010005730 R-SNARE Proteins Proteins 0.000 description 1
- 102000002215 Synaptobrevin Human genes 0.000 description 1
- 108030001722 Tentoxilysin Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002576 laryngoscopy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19856897A DE19856897A1 (de) | 1998-12-10 | 1998-12-10 | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
| PCT/EP1999/009791 WO2000033863A2 (de) | 1998-12-10 | 1999-12-10 | Therapeutikum zur unterdrückung von schnarchgeräuschen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20012716L NO20012716L (no) | 2001-06-01 |
| NO20012716D0 NO20012716D0 (no) | 2001-06-01 |
| NO328762B1 true NO328762B1 (no) | 2010-05-10 |
Family
ID=7890562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012716A NO328762B1 (no) | 1998-12-10 | 2001-06-01 | Anvendelse av klostridiumtoksin eller kompleks derav for fremstilling av et terapeutisk middel |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6573241B1 (zh) |
| EP (1) | EP1137430B1 (zh) |
| JP (1) | JP4700811B2 (zh) |
| KR (1) | KR100859556B1 (zh) |
| CN (1) | CN1186095C (zh) |
| AT (1) | ATE234108T1 (zh) |
| AU (1) | AU764744B2 (zh) |
| BR (1) | BR9915800A (zh) |
| CA (1) | CA2353469A1 (zh) |
| CZ (1) | CZ295769B6 (zh) |
| DE (2) | DE19856897A1 (zh) |
| DK (1) | DK1137430T3 (zh) |
| ES (1) | ES2192880T3 (zh) |
| HK (1) | HK1040636B (zh) |
| HU (1) | HUP0104702A3 (zh) |
| IL (2) | IL143528A0 (zh) |
| NO (1) | NO328762B1 (zh) |
| PL (1) | PL202908B1 (zh) |
| PT (1) | PT1137430E (zh) |
| RU (1) | RU2243783C2 (zh) |
| WO (1) | WO2000033863A2 (zh) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
| DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
| US20100104631A1 (en) * | 2001-08-13 | 2010-04-29 | Lipella Pharmaceuticals Inc. | Method of treatment for bladder dysfunction |
| US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US7183066B2 (en) * | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
| US20060057165A1 (en) * | 2004-09-10 | 2006-03-16 | Dimitrios Dimitrakoudis | Clostridium botulinum toxin formulation and method for reducing weight |
| CA2948238A1 (en) * | 2005-06-14 | 2006-12-28 | Revance Therapeutics, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
| US20150258183A1 (en) | 2006-06-07 | 2015-09-17 | Botulinum Toxin Research Associates, Inc. | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect |
| US8926991B2 (en) | 2005-06-14 | 2015-01-06 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
| CN103315954A (zh) | 2005-07-18 | 2013-09-25 | 麻萨诸塞州洛厄尔大学 | 制备与使用纳米乳剂的组合物和方法 |
| MX2008006750A (es) | 2005-12-01 | 2008-09-03 | Univ Massachusetts Lowell | Nanoemulsiones de botulinum. |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| WO2008140594A2 (en) * | 2006-12-01 | 2008-11-20 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
| CA2671447A1 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Amphiphilic entity nanoparticles |
| WO2008151022A2 (en) | 2007-05-31 | 2008-12-11 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| BRPI0914630A2 (pt) * | 2008-06-26 | 2019-09-24 | Anterios Inc | liberação dérmica |
| EP2364168A1 (en) | 2008-12-04 | 2011-09-14 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| WO2010078403A2 (en) * | 2008-12-30 | 2010-07-08 | Lipella Pharmaceuticals Inc. | Methods and compositions for diagnosing urological disorders |
| WO2011057301A1 (en) * | 2009-11-09 | 2011-05-12 | Ira Sanders | Treatment of sleep disordered breathing with neurotoxin |
| PL2677029T3 (pl) | 2011-05-19 | 2017-10-31 | Ipsen Bioinnovation Ltd | Sposoby wytwarzania poddanych obróbce proteolitycznej polipeptydów |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| KR20180077343A (ko) | 2012-11-21 | 2018-07-06 | 입센 바이오이노베이션 리미티드 | 단백질 가수분해 처리된 폴리펩티드의 제조방법 |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| EP3541358A1 (en) | 2016-11-21 | 2019-09-25 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551473A (en) * | 1984-04-26 | 1985-11-05 | Schossow George W | Method of inhibiting snoring and obstructive sleep apnea |
| WO1994000481A1 (en) | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
| CA2164626C (en) * | 1993-06-10 | 2004-11-23 | K. Roger Aoki | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
| EP1147776B1 (en) * | 1993-12-28 | 2010-12-15 | Allergan, Inc. | Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms |
| US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| SE9504537D0 (sv) * | 1995-12-19 | 1995-12-19 | Jan Hedner | Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| US9316973B2 (en) | 2013-06-13 | 2016-04-19 | Lexmark International, Inc. | Heat transfer system for a fuser assembly |
-
1998
- 1998-12-10 DE DE19856897A patent/DE19856897A1/de not_active Ceased
-
1999
- 1999-12-10 CA CA002353469A patent/CA2353469A1/en not_active Abandoned
- 1999-12-10 CN CNB998139505A patent/CN1186095C/zh not_active Expired - Fee Related
- 1999-12-10 IL IL14352899A patent/IL143528A0/xx active IP Right Grant
- 1999-12-10 AT AT99964547T patent/ATE234108T1/de active
- 1999-12-10 DE DE59904569T patent/DE59904569D1/de not_active Expired - Lifetime
- 1999-12-10 US US09/857,835 patent/US6573241B1/en not_active Expired - Fee Related
- 1999-12-10 WO PCT/EP1999/009791 patent/WO2000033863A2/de active IP Right Grant
- 1999-12-10 RU RU2001116080/14A patent/RU2243783C2/ru not_active IP Right Cessation
- 1999-12-10 ES ES99964547T patent/ES2192880T3/es not_active Expired - Lifetime
- 1999-12-10 KR KR1020017006787A patent/KR100859556B1/ko not_active IP Right Cessation
- 1999-12-10 DK DK99964547T patent/DK1137430T3/da active
- 1999-12-10 PL PL349334A patent/PL202908B1/pl not_active IP Right Cessation
- 1999-12-10 EP EP99964547A patent/EP1137430B1/de not_active Expired - Lifetime
- 1999-12-10 JP JP2000586354A patent/JP4700811B2/ja not_active Expired - Fee Related
- 1999-12-10 CZ CZ20012058A patent/CZ295769B6/cs not_active IP Right Cessation
- 1999-12-10 HU HU01047020104702A patent/HUP0104702A3/hu unknown
- 1999-12-10 AU AU30374/00A patent/AU764744B2/en not_active Ceased
- 1999-12-10 BR BR9915800-0A patent/BR9915800A/pt not_active IP Right Cessation
- 1999-12-10 PT PT99964547T patent/PT1137430E/pt unknown
-
2001
- 2001-06-01 NO NO20012716A patent/NO328762B1/no not_active IP Right Cessation
- 2001-06-03 IL IL143528A patent/IL143528A/en not_active IP Right Cessation
-
2002
- 2002-03-28 HK HK02102392.8A patent/HK1040636B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9915800A (pt) | 2001-09-25 |
| AU3037400A (en) | 2000-06-26 |
| JP4700811B2 (ja) | 2011-06-15 |
| DE19856897A1 (de) | 2000-06-15 |
| PL202908B1 (pl) | 2009-08-31 |
| ATE234108T1 (de) | 2003-03-15 |
| CA2353469A1 (en) | 2000-06-15 |
| RU2243783C2 (ru) | 2005-01-10 |
| HUP0104702A2 (hu) | 2002-04-29 |
| KR100859556B1 (ko) | 2008-09-22 |
| HK1040636B (zh) | 2003-05-30 |
| IL143528A0 (en) | 2002-04-21 |
| AU764744B2 (en) | 2003-08-28 |
| WO2000033863A3 (de) | 2000-11-02 |
| CN1186095C (zh) | 2005-01-26 |
| KR20010089527A (ko) | 2001-10-06 |
| NO20012716L (no) | 2001-06-01 |
| CN1329501A (zh) | 2002-01-02 |
| CZ295769B6 (cs) | 2005-11-16 |
| HK1040636A1 (en) | 2002-06-21 |
| WO2000033863A2 (de) | 2000-06-15 |
| CZ20012058A3 (cs) | 2001-09-12 |
| PL349334A1 (en) | 2002-07-15 |
| US6573241B1 (en) | 2003-06-03 |
| PT1137430E (pt) | 2003-07-31 |
| DE59904569D1 (de) | 2003-04-17 |
| JP2002531516A (ja) | 2002-09-24 |
| IL143528A (en) | 2008-04-13 |
| ES2192880T3 (es) | 2003-10-16 |
| NO20012716D0 (no) | 2001-06-01 |
| HUP0104702A3 (en) | 2003-09-29 |
| EP1137430B1 (de) | 2003-03-12 |
| DK1137430T3 (da) | 2003-06-16 |
| EP1137430A2 (de) | 2001-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO328762B1 (no) | Anvendelse av klostridiumtoksin eller kompleks derav for fremstilling av et terapeutisk middel | |
| EP1072270B1 (en) | Botulinum toxin for treating dystonia | |
| EP0702561B1 (en) | Treatment of neuromuscular disorders and conditions with botulinum serotyp e | |
| EP0702559B1 (en) | Multiple botulinum toxins for treating neuromuscular disorders and conditions | |
| MXPA01005786A (en) | Therapeutic agent for the suppression of snoring noises | |
| AU729661B2 (en) | Method for treating excessive sweating | |
| CA2300766C (en) | Neurotoxic component of botulinum toxin for treating cervical dystonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |